SABCS 2020: Salvage Chemo Appears Ineffective For High Risk, ER-Positive, HER2-Negative Breast Cancer

December 11 2020 - In patients with estrogen receptor (ER)-positive, HER2-negative breast cancer that is resistant to neoadjuvant endocrine therapy, the use of salvage neoadjuvant chemotherapy is not likely to induce a complete or near complete response, according to findings presented at the 2020 San Antonio Breast Cancer Symposium.

SABCS 2020: Pembrolizumab Plus Chemo Continues to Shine in New KEYNOTE-355 Analysis

December 11 2020 - Pembrolizumab plus chemotherapy improved the progression-free survival, overall response rate, durable complete remission, and duration of response for patients with locally recurrent, unresectable or metastatic triple negative breast cancer (TNBC) with tumors expressing PD-L1 and a combined positive score (CPS) of 10 or more, according to new findings from the KEYNOTE-355 trial.

SABCS 2020: Novel Oral Taxane Demonstrates Efficacy in CONTESSA Trial

December 11 2020 - An all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival (PFS) and other endpoints, compared with capecitabine alone, in patients with HER2-negative, hormone receptor (HR)-positive metastatic breast cancer (MBC), according to findings from the CONTESSA trial.

SABCS 2020: Some Older Women Can Safely Skip Radiation After Breast Conserving Surgery

December 10 2020 - Omitting radiation after breast-conserving surgery may not impact 10-year survival rates in women 65 years or older with hormone receptor-positive, early invasive breast cancer, suggest long-term follow up results from the PRIME II trial. The findings were presented at the 2020 San Antonio Breast Cancer Symposium.

SABCS 2020: Women Undergoing Mastectomy and Reconstruction Surgery Face Addiction Risk

December 10 2020 - Women who undergo mastectomy and reconstruction surgery may face the risk of long-term dependence on opioids and sedative-hypnotic drugs, according to research presented at the 2020 San Antonio Breast Cancer Symposium.

SABCS 2020: Palbociclib Did Not Improve Disease-Free Survival in PENELOPE-B Trial

December 10 2020 - The addition of 1 year of the CDK4/6 inhibitor palbociclib to endocrine therapy did not improve invasive disease-free survival (IDFS) in hormone receptor (HR)-positive, HER2-negative primary breast cancer in patients at high risk for relapse following neoadjuvant chemotherapy, according to results from the PENELOPE-B trial.

SABCS 2020: Abemaciclib Shines in monarchE Trial

December 09 2020 - Compared to endocrine therapy alone, abemaciclib plus endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, node-positive, early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, according to extended follow-up data from the phase 3 monarchE trial presented at the 2020 San Antonio Breast Cancer Symposium.

SABCS 2020: RxPONDER Trial Identifies Women with Breast Cancer Who Can Skip Chemotherapy

December 09 2020 - Postmenopausal women with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer who receive adjuvant endocrine therapy and have an Oncotype Dx test recurrence score of 0 to 25 can safely avoid chemotherapy.